ES2166090T3 - Composiciones transdermicas que contienen levosimendan. - Google Patents

Composiciones transdermicas que contienen levosimendan.

Info

Publication number
ES2166090T3
ES2166090T3 ES97929320T ES97929320T ES2166090T3 ES 2166090 T3 ES2166090 T3 ES 2166090T3 ES 97929320 T ES97929320 T ES 97929320T ES 97929320 T ES97929320 T ES 97929320T ES 2166090 T3 ES2166090 T3 ES 2166090T3
Authority
ES
Spain
Prior art keywords
compositions containing
transdermal compositions
transdermal
levosimenden
containing levosimendan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97929320T
Other languages
English (en)
Inventor
Arto Urtti
Jouni Hirvonen
Lasse Lehtonen
Saila Antila
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Application granted granted Critical
Publication of ES2166090T3 publication Critical patent/ES2166090T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE PRESENTA UN PROCEDIMIENTO PARA LA ADMINISTRACION TRANSDERMICA DE LEVOSIMENDAN O DE (-)-[[4-(1,4,5,6-TETRAHIDRO4-METIL-6-OXO-3-PIRIDAZINIL)FENIL HIDRAZONO]PROPANODINITRILO O UNA SAL FARMACOLOGICAMENTE ACEPTABLES DE LOS MISMOS. LAS PREPARACIONES TRANSDERMICAS DE LEVOSIMENDAN PUEDEN TENER LA FORMA POR EJEMPLO DE POMADA, EMULSION, LOCION, SOLUCION, GEL, CREMA, PARCHE O DISPOSITIVO DE SUMINISTRO TRANSDERMICO QUE INCLUYA UN DISPOSITIVO IONTOFORETICO.
ES97929320T 1996-07-05 1997-06-26 Composiciones transdermicas que contienen levosimendan. Expired - Lifetime ES2166090T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9614098.3A GB9614098D0 (en) 1996-07-05 1996-07-05 Transdermal delivery of levosimendan

Publications (1)

Publication Number Publication Date
ES2166090T3 true ES2166090T3 (es) 2002-04-01

Family

ID=10796379

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97929320T Expired - Lifetime ES2166090T3 (es) 1996-07-05 1997-06-26 Composiciones transdermicas que contienen levosimendan.

Country Status (13)

Country Link
US (1) US6183771B1 (es)
EP (1) EP0941063B1 (es)
JP (1) JP4148996B2 (es)
AT (1) ATE206910T1 (es)
AU (1) AU720504B2 (es)
DE (1) DE69707493T2 (es)
DK (1) DK0941063T3 (es)
ES (1) ES2166090T3 (es)
GB (1) GB9614098D0 (es)
GR (1) GR3037083T3 (es)
NZ (1) NZ333306A (es)
PT (1) PT941063E (es)
WO (1) WO1998001111A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI973804A (fi) * 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
FI974578A (fi) * 1997-12-19 1999-06-20 Orion Yhtymae Oyj Menetelmä levosimendaanin antamiseksi
FI980901A (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
FI105389B (fi) * 1998-04-23 2000-08-15 Orion Yhtymae Oyj Menetelmä levosimendaaniannon siedettävyyden seuraamiseksi
FI980902A (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia
FI104718B (fi) * 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä
FI981473A (fi) * 1998-06-25 1999-12-26 Orion Yhtymae Oyj Menetelmä pulmonaalihypertension hoitamiseksi
WO2000045795A2 (en) * 1999-02-05 2000-08-10 Cipla Limited Topical sprays comprising a film forming composition
EP1169025B1 (en) * 1999-04-01 2005-08-24 Alza Corporation Transdermal drug delivery devices comprising a polyurethane drug reservoir
GB9915179D0 (en) * 1999-06-29 1999-09-01 Orion Corp A method for the treatment or prevention of coronary graft vasospasm
FI109659B (fi) * 1999-09-10 2002-09-30 Orion Yhtymae Oyj Levosimendaanin farmaseuttisia liuoksia
FI20002755A0 (fi) 2000-12-15 2000-12-15 Orion Yhtymae Oyj Menetelmä erektiilin dysfunktion hoitamiseen
KR100554649B1 (ko) * 2003-06-09 2006-02-24 주식회사 아이센스 전기화학적 바이오센서
CN105456181A (zh) 2008-06-19 2016-04-06 Lts罗曼治疗方法有限公司 阳离子活性剂透皮输运组合物
DE102009008256A1 (de) * 2009-02-10 2010-08-12 Lts Lohmann Therapie-Systeme Ag Prodrugs vom Typ N-hydroxylierter Amidine, Guanidine und/oder Aminohydrazone zur Applikation über die Haut
WO2010095537A1 (ja) 2009-02-18 2010-08-26 久光製薬株式会社 経皮吸収製剤
WO2012093404A2 (en) 2011-01-03 2012-07-12 Gufic Biosciences Limited Parenteral formulations of levosimendan
AU2017326175B2 (en) 2016-09-13 2022-01-27 The Regents Of The University Of Michigan Fused 1,4-diazepines as BET protein degraders
EP4076398A4 (en) 2019-12-16 2024-01-03 Tenax Therapeutics, Inc. LEVOSIMENDAN TO TREAT PULMONARY HYPERTENSION ACCOMPANIED BY HEART FAILURE BY MEANS OF PRESERVED EJECTION FRACTION (PH-HF-PEF)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB9111732D0 (en) 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB2256135B (en) 1991-05-31 1995-01-18 Orion Yhtymae Oy Transdermal administration of 4-substituted imidazoles
GB2266841A (en) 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments

Also Published As

Publication number Publication date
ATE206910T1 (de) 2001-11-15
JP2000514081A (ja) 2000-10-24
WO1998001111A1 (en) 1998-01-15
EP0941063B1 (en) 2001-10-17
GR3037083T3 (en) 2002-01-31
AU720504B2 (en) 2000-06-01
AU3345997A (en) 1998-02-02
JP4148996B2 (ja) 2008-09-10
GB9614098D0 (en) 1996-09-04
DK0941063T3 (da) 2001-12-17
NZ333306A (en) 2000-03-27
DE69707493D1 (de) 2001-11-22
US6183771B1 (en) 2001-02-06
EP0941063A1 (en) 1999-09-15
DE69707493T2 (de) 2002-04-11
PT941063E (pt) 2002-04-29

Similar Documents

Publication Publication Date Title
ES2166090T3 (es) Composiciones transdermicas que contienen levosimendan.
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
EE9800223A (et) Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
DE69710065D1 (de) Androsten-derivate
DE69738000D1 (de) Neue Arzneiformulierung enthaltend Budesonide
NZ236823A (en) Topical pharmaceutical and cosmetic compositions containing a salt of cholanic acid, a lipid and optionally a pharmaceutically or cosmetically active substance
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
BG103552A (en) Therapeutical forms
NO952906D0 (no) Farmasöytisk formulering for behandling av nikotinavhengighet
EE200200283A (et) Zolmitriptaani sisaldavad ravimpreparaadid
YU32196A (sh) Upotreba jedinjenja za pripremanje leka korisnog za inhibiranje migracije vaskularnih ćelija glatkog mišića
FR2681784B1 (fr) Composition dermatologique et/ou cosmetologique contenant des retinouides et utilisation de nouveaux retinouides.
FR2731907B1 (fr) Composition dermatologique et/ou cosmetique depigmentante et utilisation dans une methode cosmetique
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
SE9402880D0 (sv) New peptide derivatives
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
CA2259194A1 (en) Transdermal compositions containing levosimendan
ATE260655T1 (de) Verwendung von stickstoffhaltigen aromatischen heterozyklusderivaten zur topischen behandlung von epithelerkrankungen
AU4944899A (en) New pharmaceutically active compounds
NO964688L (no) Ny peptid-aktivsubstans og fremstilling av denne
BG101346A (en) 4-thio-1-azabicyclo[3.2.0]heptan-3-imino-2- isopropyliden-7-oxoanalogues of alpha-lactams, methods for their preparation and usage

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 941063

Country of ref document: ES